BUSINESS● LOWAug 14 · Aug 14, 2026, 12:33 PM
VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M
Seeking Alpha Tech
VistaGen Therapeutics reported GAAP Earnings Per Share (EPS) of -$0.30, beating expectations by $0.06, and revenue of $1.48 million, surpassing estimates by $1.31 million. This indicates better-than-expected financial results for the company.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS45m agoGold market consolidating rather than entering bear market, Metals Focus analyst saysSeeking Alpha TechBUSINESS46m agoCollegium resolves Nucynta patent dispute with GrünenthalSeeking Alpha Tech